Girish Amin, MD
Hematology · Brick, NJNPI 1720071731
Payments from drug & device makers
Across 97 payments — averaging $529.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$25K
- Eli Lilly$18K
- Genentech, Inc.$7K
- Gilead$232
- Daiichi Sankyo Inc.$158
- Novartis$124
- plus $1K from 31 others
What the payments were for
- Food & beverage$1,13569%
- Education$50631%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 7 | $25,410 |
| Eli Lilly | 3 | $17,726 |
| Genentech, Inc. | 8 | $6,630 |
| Gilead(2 entities) | 12 | $232 |
| Daiichi Sankyo Inc. | 7 | $158 |
| Novartis | 6 | $124 |
| Regeneron Healthcare Solutions, Inc. | 5 | $84 |
| Boston Scientific | 1 | $83 |
| Sanofi | 5 | $78 |
| AstraZeneca | 3 | $78 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $70 |
| Pfizer | 3 | $46 |
| Johnson & Johnson | 3 | $44 |
| Amgen | 1 | $40 |
| AbbVie | 2 | $38 |
| Pharmacosmos Therapeutics Inc. | 2 | $38 |
| Springworks Therapeutics, Inc. | 2 | $37 |
| Telix Pharmaceuticals | 2 | $35 |
| Bristol Myers Squibb | 1 | $34 |
| Geron Corporation | 2 | $33 |
| Merck | 2 | $32 |
| E.r. Squibb & Sons, L.L.C. | 2 | $32 |
| Eisai Inc. | 2 | $31 |
| Genentech USA, Inc. | 2 | $30 |
| AVEO Pharmaceuticals, Inc. | 1 | $28 |
| Avyxa Pharma, LLC | 1 | $25 |
| Taiho Oncology, Inc. | 1 | $24 |
| Bayer | 1 | $21 |
| Mirati Therapeutics, Inc. | 1 | $21 |
| Ipsen Biopharmaceuticals, Inc | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Exelixis Inc. | 1 | $17 |
| Blueprint Medicines Corporation | 1 | $16 |
| Boehringer Ingelheim | 1 | $16 |
| Spectrum Pharmaceuticals Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
How this compares
$51,389 in reported general payments places this provider in the 85th percentile of 43 hematology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 82 | $1,404,332 |
| OjjaaraMomelotinib Dihydrochloride | 28 | $712,928 |
| BrukinsaZanubrutinib | 37 | $516,120 |
| PomalystPomalidomide | 23 | $452,940 |
| XtandiEnzalutamide | 28 | $452,173 |
| Lenalidomide | 28 | $412,585 |
| ReblozylLuspatercept-Aamt | 17 | $327,198 |
| LynparzaOlaparib | 18 | $303,155 |
| IbrancePalbociclib | 19 | $285,510 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 13 | $270,309 |
| RevlimidLenalidomide | 12 | $268,383 |
| Abiraterone Acetate | 81 | $244,350 |
| VenclextaVenetoclax | 16 | $230,461 |
| AlecensaAlectinib Hcl | 12 | $222,936 |
| ImbruvicaIbrutinib | 12 | $126,172 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $25,410 | $1,404,33282 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst, Reblozyl | $32 | $780,13840 claims |
| Astellas Pharma US IncXtandi | $16 | $452,17328 claims |
| PfizerIbrance, Eliquis | $46 | $355,304109 claims |
| AstraZenecaLynparza | $78 | $303,15518 claims |
| Bristol Myers SquibbRevlimid | $34 | $268,38312 claims |
| AbbVieVenclexta | $38 | $230,46116 claims |
| Genentech USA, Inc.Alecensa | $30 | $222,93612 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $70 | $126,17212 claims |
| Johnson & JohnsonXarelto | $44 | $20,91924 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 43 hematology providers in New Jersey.
Other hematology in Brick
- Randi KatzBrick$15K
- Ahmed GalalMorristown$2.1M
- Mansi ShahNew Brunswick$1.7M
- Rahul MatnaniRutherford$175K
- Fermina MazzellaNewark$89K
- Ogechukwu EginiNew Brunswick$89K
- Claire PhilippNew Brunswick$53K
- Karleung SiuTeaneck$45K
- Clare SunBasking Ridge$35K
- Muhammad AbbasiMountain Lakes$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.